Free tool
FAERS Monitor: Pylarify
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214793 or its brand name (Pylarify, Piflufolastat F-18). Reports on generic versions are filed under their own applications.
Reports
334
Serious
14
4% of reports
Hospitalization
4
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- radioisotope scan abnormal104
- drug ineffective75
- product dispensing error36
- product dose omission issue32
- underdose30
- product dispensing issue29
- intercepted product administration error26
- intercepted product dispensing error22
- product preparation error15
- occupational exposure to radiation8
- wrong product administered8
- dizziness7
- fatigue7
- product contamination7
- product administration error6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 6 |
| 2022 | 31 |
| 2023 | 55 |
| 2024 | 24 |
| 2025 | 78 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| occupational exposure to radiationSignal | 8 | 18677.2 | 8547.6 | 101,295 |
| radioisotope scan abnormalSignal | 104 | 10871.8 | 9095.9 | 954,949 |
| intercepted product dispensing errorSignal | 22 | 847.1 | 564.0 | 17,523 |
| product dispensing issueSignal | 29 | 429.8 | 303.2 | 11,903 |
| intercepted product administration errorSignal | 26 | 214.3 | 148.0 | 5,292 |
| product contaminationSignal | 7 | 124.1 | 59.6 | 735 |
| product dispensing errorSignal | 36 | 104.3 | 76.6 | 3,577 |
| wrong product administeredSignal | 8 | 74.7 | 37.6 | 510 |
| product preparation errorSignal | 15 | 46.0 | 28.1 | 616 |
| underdoseSignal | 30 | 25.9 | 18.4 | 695 |
| product administration errorSignal | 6 | 18.7 | 8.5 | 84 |
| product dose omission issueSignal | 32 | 6.9 | 4.9 | 156 |
| drug ineffectiveSignal | 75 | 3.6 | 2.9 | 146 |
| dizziness | 7 | 0.9 | 0.4 | 0 |
| fatigue | 7 | 0.6 | 0.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.